GILD
NASDAQGilead Sciences Inc.
Price$133.70+0.29 (+0.22%)
01:30 PM07:45 PM
News · 26 weeks102-50%
2025-10-262026-04-19
Mix5490d
- Insider25(46%)
- Other14(26%)
- SEC Filings5(9%)
- Earnings4(7%)
- Analyst3(6%)
- M&A2(4%)
- Other1(2%)
Latest news
25 items- PRGilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa
- PRGilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender OfferGilead Sciences, Inc. (NASDAQ:GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC's determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant rev
- INSIDERSEC Form 4 filed by Dickinson Andrew D4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERSEC Form 4 filed by Mercier Johanna4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRPEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to
- PRTempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWETempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (NASDAQ:GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus' AI-driven Lens platform, unlocking access to broader datasets across multiple indications a
- PREQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billionGilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology companyEQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted the Company at board level in its growth to a leading global clinical-stage ADC companyAMSTERDAM, April 7, 2026 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund ("EQT Life Sciences") has exited its minority stake in Tubulis (the "Company"), a Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences (NASDAQ:GILD). Tubulis' lead asset, TUB-040, a
- PRGilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform That Includes its Clinically-Validated Tubutecan Linker-Payload Technology and Next-Generation Platform to Expand Gilead's ADC Capabilities – Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead's oncology pipeline, focused on addressing areas of high unmet need. This press release features multimedia. View the full release here: https:/
- PRGilead Extends Tender Offer to Acquire ArcellxGilead Sciences, Inc. (NASDAQ:GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029. The tender offer, which was pr
- INSIDERSEC Form 4 filed by O'Day Daniel Patrick4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Gilead Sciences Inc.SCHEDULE 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
- PRGilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead's Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323998270/en/ The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell e
- SECSEC Form DEF 14A filed by Gilead Sciences Inc.DEF 14A - GILEAD SCIENCES, INC. (0000882095) (Filer)
- SECSEC Form DEFA14A filed by Gilead Sciences Inc.DEFA14A - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRCombination Therapies Reshape Oncology: A $748B Market Shifts Standard of CareIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna sold $432,690 worth of shares (3,000 units at $144.23), decreasing direct ownership by 2% to 131,779 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $432,690 worth of shares (3,000 units at $144.23), decreasing direct ownership by 2% to 179,191 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D converted options into 6,469 shares and covered exercise/tax liability with 3,147 shares, increasing direct ownership by 2% to 182,191 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna converted options into 6,617 shares and covered exercise/tax liability with 3,216 shares, increasing direct ownership by 3% to 134,779 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDEREVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 1,246 shares and covered exercise/tax liability with 606 shares, increasing direct ownership by 14% to 5,054 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Controllership Burkhart Erin4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChairman & CEO O'Day Daniel Patrick converted options into 20,026 shares and covered exercise/tax liability with 9,767 shares, increasing direct ownership by 2% to 652,567 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Medical Officer Berger Dietmar converted options into 2,133 shares and covered exercise/tax liability with 1,063 shares, increasing direct ownership by 6% to 18,982 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- ANALYSTJefferies initiated coverage on Gilead Sciences with a new price targetJefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00
- INSIDERChief Financial Officer Dickinson Andrew D was granted 11,090 shares, increasing direct ownership by 7% to 178,869 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)